Glioblastoma Research Organization

SMILE Checking in time remind you about Amazon Smile and how EASY and FREE it is for you to help support #glioblastoma research. Amazon donates 0.5% of the price of your eligible AmazonSmile purchases to the charitable organization of your choice (@glioblastomaresearch of course ) AmazonSmile is the SAME Amazon you know. Same products, same prices, same service. ALL YOU NEED TO DO TO SUPPORT #GLIOBLASTOMA Research is by starting your shopping at smile.amazon.com. Also now available through the Amazon App! LINK IN OUR BIO (Artwork via @saprisun )

During these incredibly uncertain times, it’s easy to get caught up with worries about what the future holds. While worrying serves as a defense mechanism for most, often times we tend to miss what is happening around us. Today, take some time to be present with those you love, to savor every bite of a meal, to pay attention to those lyrics you always miss. Tackling life one day at a time can be beneficial in different contexts. Wether you are going through a tough time or h...ave a big long-term goal, all that is in our control is our present moment, it’s the only thing we can change. So for now, make your favorite beverage, change into your favorite outfit (or pajamas), call someone you love! Make each moment the best it can possibly be! Wishing you all a wonderful and mindful weekend Love, The Glioblastoma Research Organization (Artwork via @endbraincancer)

GBM NEWS part 2 via @pharmacytimes The researchers conducted genomic analyses of recurrent glioblastoma tumors from patients who had been treated at Duke with the poliovirus therapy, as well as others who had received checkpoint inhibitors. Among both treatment groups, the researchers observed that the patients with recurrent glioblastoma tumors with fewer mutations survived longer than patients with tumors with more mutations. However, they also found that this was speci...fic to patients with recurrent tumors, as the same pattern did not occur among patients with newly diagnosed disease who had not received prior treatment. "This suggests that chemotherapy, which is the standard of care for newly diagnosed glioblastoma, might be altering the inflammatory response in these tumors," Ashley said in the press release. He also noted that chemotherapy may be acting as a primer that triggers the development of an inflammation process in recurrent tumors. Ashley added that the results from this study may be applicable to other types of tumors than glioblastoma, such as kidney and pancreatic cancers. Both of these cancer types present with similar correlations between low tumor mutations and improved response to immunotherapies. (Artwork via @atypical.artistry )

#WARRIORWEDNESDAY: Your story with #glioblastoma. Today, we share Jasmine’s story We think I’ve had the cancer for three years but I just started having the side effects here in May 2020. ... My family went to a funeral out of state leaving me home to watch the house and animals. It was during Summer break so I didn’t have school or anything. And I started having really bad migraines. I went to my doctor and he thought it was a side effect of medicine I was on. And after like three days we found it wasn’t. So I went to a hospital-on June 2nd- and they thought it was a cyst kind of thing. And then they took me to Children’s Hospital. And they found out a few days later I had a brain tumor the size of an orange. A small one, but the doctor explained that’s still kind of big, for a brain tumor. And on June 9th they took the tumor out. I got released. I was doing fine. And on that next week I believe, we found out I had glioblastoma grade four. I remember we were all surprised including my doctors because they said it is usually common in older men and women. But I began radiation. And afterwards, on August 19th, I had six seizures they believe, and I was rushed to the hospital. And soon after I started chemo and now I’m about to work on my third round of chemotherapy. Please join us in sending Jasmine all our love and support as she braves through her battle with glioblastoma featured in our series, please email us at [email protected] or DM us

GBM NEWS PART 1 via @pharmacytimes The treatment of glioblastoma brain tumors has remained a significant challenge, as some tumors respond to new immunotherapies after they've grown back, whereas others do not. Although the tumors often do lead to mortality, 20% of patients live beyond predicted survival times. For this reason, many researchers have investigated what causes some patients’ tumors to respond to immunotherapies so that they could pinpoint how to treat others... more effectively. A recent study by Duke's Preston Robert Tisch Brain Tumor Center added to this body of research on glioblastoma, finding that recurring glioblastoma tumors with very few mutations respond significantly better to immunotherapies than similar tumors with multiple mutations. The results of the study may help clinicians target immunotherapies directly at tumors with the highest likelihood of responding to the treatment, which may also allow for the discovery of new approaches to improving the efficacy of other immunotherapies as well, according to the authors. "It's been frustrating that glioblastoma is incurable and we've had limited progress improving survival despite many promising approaches," said senior author David Ashley, MD, PhD, professor in the departments of Neurosurgery, Medicine, Pediatrics and Pathology at Duke University School of Medicine (Duke), in a press release. "We've had some success with several different immunotherapies, including the poliovirus therapy developed at Duke. And while it's encouraging that a subset of patients who do well when the therapies are used to treat recurrent tumors, about 80% of patients still die." (Artwork via @ay.art.04 )